Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells

Dimeric VIPR2 forms the minimal functional unit that effectively promotes growth and metastasis of breast cancer. Therefore, dimeric VIPR2 is a potential therapeutic target for breast cancer, and TM3-4-peptides are potential anti-cancer drug candidates to suppress cancer progression.